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Disseminated Histoplasmosis after Vedolizumab Treatment for Ulcerative Colitis
Ivanna Murskyj, David Henkin, Joydip Joy, Nina Garza, Vinay Shah

Henry Ford Health System, Detroit, Michigan
Abstract
We present a case of disseminated histoplasmosis in a nonendemic area in a patient following treatment with vedolizumab,
an anti-integrin monoclonal antibody, for ulcerative colitis. The
patient was admitted for fevers, elevated liver function tests and
liver biopsy showed granulomas with encapsulated yeasts,
confirming Histoplasma capsulatum infection. Only two cases
of histoplasmosis after vedolizumab have been reported.

Background
• Epidemiology: Histoplasmosis is one of the four known
systemic mycoses known to be endemic in the Ohio and
Mississippi River valleys in the United States and much of
Latin America.
• Transmission: Systemic mycotic infections are acquired
through inhalation of spores found in the environment. Sources
of Histoplasma capsulatum spore exposure include farming,
cutting down trees, and remodeling or demolition of old
buildings.
• Clinical features: It can cause pneumonia and forming
granulomas similar to tuberculosis, but it is incapable of being
transmitted person-to-person. If immunocompromised, H.
capsulatum can disseminate and cause a variety of symptoms
including fever, fatigue, weight loss, lymphadenopathy,
hepatomegaly, splenomegaly with laboratory findings of
anemia, leukopenia, thrombocytopenia, elevated hepatic
enzymes, bilirubin, lactate dehydrogenase and ferritin.

Case Description
Patient demographics: 41 year old Michigan native with past
medical history significant for ulcerative colitis
History of present illness: The patient had recently been
started on vedolizumab, and tolerated two transfusions. A
few weeks after the patient’s last vedolizumab infusion, he
presented to urgent care endorsing home temperatures of
102-103°F. A follow up with his primary care physician and
subsequent lab work revealed elevated aspartate transaminase
(AST) of 266 and alanine transaminase (ALT) of 232 and he
was sent to the emergency department for further evaluation.
Social history: He lived his entire life in Michigan and had no
recent travel outside the state. At home, the patient was
exposed to a rabbit, dog and gecko and he worked as a
construction worker. He did endorse frequently chopping
wood in the forest and multiple other outdoor activities.

Hospital Course
• Throughout his admission, the patient had cyclic nightly
fevers with temperatures reaching 102-103°F. Infectious
workup to rule out atypical opportunistic infections was done,
including HSV, HIV, Hep B, Hep C, Hep A, C diff. CMV,
Giardia, Syphilis and Cryptosporidium.
• MRCP was performed given his transaminitis and was
suggestive of possible small duct primary sclerosing
cholangitis (PSC). Liver biopsy was done to further
characterize and confirm the PSC, but the pathology report
showed granulomas, encapsulated yeasts, and no evidence of
PSC.
• Test results revealed positive urine histoplasma antigen and
positive blood beta-d-glucan. With suspected
disseminated histoplasmosis, the patient was started on IV
liposome amphotericin B for one week after which he was
transitioned to oral itraconazole for 3-6 months. His fevers
resolved, and his LFT’s returned to normal.

Figure 1. Fever curve before and after initiation of antifungal
therapy.

Discussion
• Histoplasma capsulatum is endemic in the Mississippi River
valleys, but is rare in Michigan
• There have only been two case reports of H. capsulatum
infection associated with vedolizumab, only 1 of which
progressing to disseminated histoplasmosis
• This patient had a fondness for outdoor activities as well as
recent immunomodulator use that increased his risk for
disseminated fungal infection
• Maintaining a broad differential in patients on
immunomodulator therapy is critical
• Histoplasmosis can present in a variety of ways, and along
with other systemic mycoses, should be considered in patients
presenting with non-specific systemic symptoms.
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